DDrare: Database of Drug Development for Rare Diseases

127. 前頭側頭葉変性症
［臨床試験数：74，薬物数：83（DrugBank：28），標的遺伝子数：29，標的パスウェイ数：99］

Searched query = "Frontotemporal lobar degeneration", "Frontotemporal dementia", "Semantic dementia"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

Drug = (R)-[N-metil-11C1-PK11195(PK); 18F-AV-1451; 18F-AV-45; 18F-FDG; 18F-RO6958948; AL; AL001; AMIODARONE; Amantadine; Amiodarone; Amyvid; BIIB092; Behavioral: Cognitive and Behavioral experimental tasks; Behavioral: ECOCAPTURE; Behavioral: ICM_APATHY_TASKS; C-11 PiB; Carbonate; Chloride; Citalopram; Davunetide; Davunetide (AL-108, NAP); Diagnostic Test: Elecsys (Roche) Abeta42, Ttau and Ptau; Diagnostic Test: Flutemetamol F18 Injection; Diagnostic Test: Lumipulse (Fujirebio) Abeta42, Ttau and Ptau; Diagnostic Test: Neuropsychological assessment; Diagnostic Test: Supplementary Neuropsychological Assessment - Parkinson's Disease; Diagnostic Test: [18F]-RO6958948; Donepezil; EVP-0334; F 18 T807; F-18; F-18 FDG; FRM-0334; Ferulic acid; Florbetapir (18F); Florbetapir 18F; Florbetapir 18F Injection; Flortaucipir; Flortaucipir F18; Flutemetamol; Flutemetamol F18; Galantamine; Galantamine hydrobromide; Histone Deacetylase Inhibitor; Intranasal oxytocin; LMTM; LMTM/TRx0237; Leucine; Leuco-methylthioninium bis(hydromethanesulfonate); Lithium Carbonate; Lithium carbonate; MTC TRx0014-001 capsules; Memantine; Memantine hydrochloride; Metformin; Methylprednisolone; Methylthioninium; Methylthioninium chloride; N,N,N',N'-tetramethyl-10H-phenothiazine-3,7-diaminium bis(methanesulfonate); N,N,N?,N?-tetramethyl-10H-phenothiazine-3,7-diaminium bis(methanesulfonate); N,N,N’,N’-tetramethyl-10H-phenothiazine-3,7-diaminium bis(methanesulfonate); Neurohormonal mechanisms; Novolin-R insulin; Other: 13C6 Leucine; Other: MRI; Oxytocin; PEA-LUT; PR006; Phenothiazine; Pittsburgh Compound B; Pittsburgh Compound B (C-11 PiB); Prednisone; Procedure: Brain PET scan; Saline Nasal Mist; Sirolimus; Syntocinon; T807; TRx0237; Tau (18-F-AV-1451); Tolcapone; Vizamyl; Vizamyl (flutemetamol(F-18)); [18F]PI-2620

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT03174938 (ClinicalTrials.gov)	May 15, 2017	28/5/2017	The Swedish BioFINDER 2 Study	The Swedish BioFINDER 2 Study	Dementia;Alzheimer Disease;Parkinson Disease;Lewy Body Disease;Parkinson-Dementia Syndrome;Frontotemporal Degeneration;Semantic Dementia;Progressive Nonfluent Aphasia;Progressive Supranuclear Palsy;Corticobasal Degeneration;Multiple System Atrophy;Mild Cognitive Impairment	Diagnostic Test: Flutemetamol F18 Injection;Diagnostic Test: [18F]-RO6958948;Diagnostic Test: Elecsys (Roche) Abeta42, Ttau and Ptau;Diagnostic Test: Lumipulse (Fujirebio) Abeta42, Ttau and Ptau	Skane University Hospital	Lund University	Recruiting	20 Years	100 Years	All	1505	N/A	Sweden
2	EUCTR2017-000094-36-SE (EUCTR)	31/03/2017	30/01/2017	The BioFINDER 2 study - improved diagnostics and increased understanding of the underlying mechanisms of cognitive disorders	The BioFINDER 2 study - improved diagnostics and increased understanding of the pathophysiology of cognitive disorders	Neurodegenerative disorders with Tau-pathology; including, but not limited to, Alzheimers disease, progressive supranuclear palsy,frontotemporal dementia, corticobasal degeneration and mild cognitive impairment. MedDRA version: 19.1;Level: PT;Classification code 10053643;Term: Neurodegenerative disorder;System Organ Class: 10029205 - Nervous system disorders MedDRA version: 19.1;Classification code 10012267;Term: Dementia;Classification code 10067889;Term: Dementia with Lewy bodies;Level: HLGT;Classification code 10028037;Term: Movement disorders (incl parkinsonism);Classification code 10012271;Term: Dementia Alzheimer's type;Level: HLT;Classification code 10001897;Term: Alzheimer's disease (incl subtypes);Level: LLT;Classification code 10009846;Term: Cognitive impairment;Classification code 10048598;Term: Cognitive disorders;Classification code 10001896;Term: Alzheimer's disease;Classification code 10012285;Term: Dementia due to Pick's disease;Classification code 10036813;Term: Progressive supranuclear palsy;Classification code 10074616;Term: Prodromal Alzheimer's;Therapeutic area: Analytical, Diagnostic and Therapeutic Techniques and Equipment [E] - Diagnosis [E01]	Product Name: 18F-RO6958948 Trade Name: Vizamyl (flutemetamol(F-18)) Product Name: Vizamyl	Skåne University Hospital	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes		Phase 2	Sweden

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

NCT03174938
(ClinicalTrials.gov)

May 15, 2017

28/5/2017

The Swedish BioFINDER 2 Study

Dementia;Alzheimer Disease;Parkinson Disease;Lewy Body Disease;Parkinson-Dementia Syndrome;Frontotemporal Degeneration;Semantic Dementia;Progressive Nonfluent Aphasia;Progressive Supranuclear Palsy;Corticobasal Degeneration;Multiple System Atrophy;Mild Cognitive Impairment

Diagnostic Test: Flutemetamol F18 Injection;Diagnostic Test: [18F]-RO6958948;Diagnostic Test: Elecsys (Roche) Abeta42, Ttau and Ptau;Diagnostic Test: Lumipulse (Fujirebio) Abeta42, Ttau and Ptau

Skane University Hospital

Lund University

Recruiting

20 Years

100 Years

All

1505

N/A

Sweden

EUCTR2017-000094-36-SE
(EUCTR)

31/03/2017

30/01/2017

The BioFINDER 2 study - improved diagnostics and increased understanding of the underlying mechanisms of cognitive disorders

The BioFINDER 2 study - improved diagnostics and increased understanding of the pathophysiology of cognitive disorders

Neurodegenerative disorders with Tau-pathology; including, but not limited to, Alzheimers disease, progressive supranuclear palsy,frontotemporal dementia, corticobasal degeneration and mild cognitive impairment.
MedDRA version: 19.1;Level: PT;Classification code 10053643;Term: Neurodegenerative disorder;System Organ Class: 10029205 - Nervous system disorders
MedDRA version: 19.1;Classification code 10012267;Term: Dementia;Classification code 10067889;Term: Dementia with Lewy bodies;Level: HLGT;Classification code 10028037;Term: Movement disorders (incl parkinsonism);Classification code 10012271;Term: Dementia Alzheimer's type;Level: HLT;Classification code 10001897;Term: Alzheimer's disease (incl subtypes);Level: LLT;Classification code 10009846;Term: Cognitive impairment;Classification code 10048598;Term: Cognitive disorders;Classification code 10001896;Term: Alzheimer's disease;Classification code 10012285;Term: Dementia due to Pick's disease;Classification code 10036813;Term: Progressive supranuclear palsy;Classification code 10074616;Term: Prodromal Alzheimer's;Therapeutic area: Analytical, Diagnostic and Therapeutic Techniques and Equipment [E] - Diagnosis [E01]

Product Name: 18F-RO6958948
Trade Name: Vizamyl (flutemetamol(F-18))
Product Name: Vizamyl

Skåne University Hospital

NULL

Authorised-recruitment may be ongoing or finished

Female: yes
Male: yes

Phase 2

Sweden